RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals

Influenza viruses (IVs) tend to rapidly develop resistance to virus-directed vaccines and common antivirals targeting pathogen determinants, but novel host-directed approaches might preclude resistance development. To identify the most promising cellular targets for a host-directed approach against influenza, we performed a comparative small interfering RNA (siRNA) loss-of-function screen of IV replication in A549 cells. Analysis of four different IV strains including a highly pathogenic avian H5N1 strain, an influenza B virus (IBV) and two human influenza A viruses (IAVs) revealed 133 genes required by all four IV strains. According to gene enrichment analyses, these strain-independent host genes were particularly enriched for nucleocytoplasmic trafficking. In addition, 360 strain-specific genes were identified with distinct patterns of usage for IAVs versus IBV and human versus avian IVs. The strain-independent host genes served to define 43 experimental and otherwise clinically approved drugs, targeting reportedly fourteen of the encoded host factors. Amongst the approved drugs, the urea-based kinase inhibitors (UBKIs) regorafenib and sorafenib exhibited a superior therapeutic window of high IV antiviral activity and low cytotoxicity. Both UBKIs appeared to block a cell signaling pathway involved in IV replication after internalization, yet prior to vRNP uncoating. Interestingly, both compounds were active also against unrelated viruses including cowpox virus (CPXV), hantavirus (HTV), herpes simplex virus 1 (HSV1) and vesicular stomatitis virus (VSV) and showed antiviral efficacy in human primary respiratory cells. An in vitro resistance development analysis for regorafenib failed to detect IV resistance development against this drug. Taken together, the otherwise clinically approved UBKIs regorafenib and sorafenib possess high and broad-spectrum antiviral activity along with substantial robustness against resistance development and thus constitute attractive host-directed drug candidates against a range of viral infections including influenza.

[1]  Kathy Hancock.  Influenza A Virus , 2020, Definitions.

[2]  H. Einsele,et al.  Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose‐ and time‐dependent manner , 2018, Clinical and experimental immunology.

[3]  Jorge Andrade,et al.  Genome-wide CRISPR/Cas9 Screen Identifies Host Factors Essential for Influenza Virus Replication , 2018, Cell reports.

[4]  K. Kehn-Hall,et al.  Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein Function in the Cellular Secretory Pathway , 2017, Journal of Virology.

[5]  J. Hicks,et al.  Sorafenib combined with HER‐2 targeted vaccination can promote effective T cell immunity in vivo , 2017, International immunopharmacology.

[6]  PerwitasariOlivia,et al.  Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication , 2015 .

[7]  K. Kehn-Hall,et al.  Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection , 2015, Front. Microbiol..

[8]  P. Dent,et al.  GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases , 2015, Journal of cellular physiology.

[9]  B. Oliva,et al.  Targeting Importin-α7 as a Therapeutic Approach against Pandemic Influenza Viruses , 2015, Journal of Virology.

[10]  E. van der Ryst.  Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection , 2015, Frontiers in immunology.

[11]  G. Duverlie,et al.  The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro. , 2015, Antiviral research.

[12]  Juancarlos Chan,et al.  Gene Ontology Consortium: going forward , 2014, Nucleic Acids Res..

[13]  L. van Doorn,et al.  In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122 , 2014, Antimicrobial Agents and Chemotherapy.

[14]  Indranil Banerjee,et al.  Influenza A virus uses the aggresome processing machinery for host cell entry , 2014, Science.

[15]  A. Hurt.  The epidemiology and spread of drug resistant human influenza viruses. , 2014, Current opinion in virology.

[16]  Paul Kellam,et al.  Accumulation of Human-Adapting Mutations during Circulation of A(H1N1)pdm09 Influenza Virus in Humans in the United Kingdom , 2014, Journal of Virology.

[17]  A. Helenius,et al.  Stepwise Priming by Acidic pH and a High K+ Concentration Is Required for Efficient Uncoating of Influenza A Virus Cores after Penetration , 2014, Journal of Virology.

[18]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[19]  E. Baloglu,et al.  Verdinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces Influenza A Virus Replication In Vitro and In Vivo , 2014, Journal of Virology.

[20]  Hao Zhang,et al.  The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins. , 2014, Antiviral research.

[21]  N. Tischler,et al.  Hantavirus Gn and Gc Envelope Glycoproteins: Key Structural Units for Virus Cell Entry and Virus Assembly , 2014, Viruses.

[22]  A. Herrmann,et al.  pH-Controlled two-step uncoating of influenza virus. , 2014, Biophysical journal.

[23]  Stephanie M. Tortorella,et al.  Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy , 2014, The Journal of Membrane Biology.

[24]  C. Futter,et al.  EGF receptor trafficking: consequences for signaling and cancer , 2014, Trends in cell biology.

[25]  S. Kauppinen,et al.  Treatment of HCV infection by targeting microRNA. , 2013, The New England journal of medicine.

[26]  Martin Büchert,et al.  A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.

[27]  G. Gabriel,et al.  Human-like PB2 627K Influenza Virus Polymerase Activity Is Regulated by Importin-α1 and -α7 , 2012, PLoS pathogens.

[28]  Theonie Anastassiadis,et al.  Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[29]  Qian Wu,et al.  cSSMD: assessing collective activity for addressing off-target effects in genome-scale RNA interference screens , 2011, Bioinform..

[30]  Ming Luo,et al.  Influenza Virus Entry , 2011, Advances in experimental medicine and biology.

[31]  M. Shaw.  The host interactome of influenza virus presents new potential targets for antiviral drugs , 2011, Reviews in medical virology.

[32]  W. Barclay,et al.  Lack of transmission of a human influenza virus with avian receptor specificity between ferrets is not due to decreased virus shedding but rather a lower infectivity in vivo. , 2011, The Journal of general virology.

[33]  A. García-Sastre,et al.  Influenza A viruses: new research developments , 2011, Nature Reviews Microbiology.

[34]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[35]  C. Punt,et al.  Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination , 2011, Clinical Cancer Research.

[36]  R. Haag,et al.  Inhibition of Influenza Virus Activity by Multivalent Glycoarchitectures with Matched Sizes , 2011, Chembiochem : a European journal of chemical biology.

[37]  Adolfo García-Sastre,et al.  Dissection of the Influenza A Virus Endocytic Routes Reveals Macropinocytosis as an Alternative Entry Pathway , 2011, PLoS pathogens.

[38]  H. Doerr,et al.  The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication , 2011, Cellular and Molecular Life Sciences.

[39]  E. Hartmann,et al.  Differential use of importin-α isoforms governs cell tropism and host adaptation of influenza virus , 2011, Nature communications.

[40]  P. Randhawa,et al.  Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication. , 2010, American journal of clinical pathology.

[41]  Lincoln Stein,et al.  Reactome: a database of reactions, pathways and biological processes , 2010, Nucleic Acids Res..

[42]  T. Kanneganti.  Central roles of NLRs and inflammasomes in viral infection , 2010, Nature Reviews Immunology.

[43]  R. Fouchier,et al.  The Epidermal Growth Factor Receptor (EGFR) Promotes Uptake of Influenza A Viruses (IAV) into Host Cells , 2010, PLoS pathogens.

[44]  T. Kuiken,et al.  Comparative Pathology of Select Agent Influenza A Virus Infections , 2010, Veterinary pathology.

[45]  S. Higgs,et al.  Endocytosis of Chikungunya Virus into Mammalian Cells: Role of Clathrin and Early Endosomal Compartments , 2010, PloS one.

[46]  G. Kochs,et al.  High yields of influenza A virus in Madin-Darby canine kidney cells are promoted by an insufficient interferon-induced antiviral state. , 2010, The Journal of general virology.

[47]  Yoshihiro Kawaoka,et al.  Cellular networks involved in the influenza virus life cycle. , 2010, Cell host & microbe.

[48]  Hui Li,et al.  PKA Regulates Vacuolar H+-ATPase Localization and Activity via Direct Phosphorylation of the A Subunit in Kidney Cells* , 2010, The Journal of Biological Chemistry.

[49]  Daniel Becker,et al.  Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication , 2010, Nature.

[50]  F. Mayer,et al.  The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro1 , 2009, The Journal of Immunology.

[51]  A. Kelso,et al.  Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation , 2009, Journal of Virology.

[52]  I. Melero,et al.  Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes , 2009, British Journal of Cancer.

[53]  R. Webster,et al.  The Influenza Virus Enigma , 2009, Cell.

[54]  T. Popow-Kraupp,et al.  Influenza B mutant viruses with truncated NS1 proteins grow efficiently in Vero cells and are immunogenic in mice. , 2009, The Journal of general virology.

[55]  Antoine M. van Oijen,et al.  Real-time single-molecule observation of rolling-circle DNA replication , 2009, Nucleic acids research.

[56]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[57]  P. Brossart,et al.  Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. , 2008, Blood.

[58]  R. Song,et al.  Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation , 2008, Leukemia.

[59]  Jin Hyun Kim,et al.  Novel Approach to the Development of Effective H5N1 Influenza A Virus Vaccines: Use of M2 Cytoplasmic Tail Mutants , 2007, Journal of Virology.

[60]  Thorsten Wolff,et al.  Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF‐κB‐inhibiting activity , 2007, Cellular microbiology.

[61]  Stefan Hippenstiel,et al.  IFNβ induction by influenza A virus is mediated by RIG‐I which is regulated by the viral NS1 protein , 2007, Cellular microbiology.

[62]  Wolfgang Huber,et al.  Analysis of cell-based RNAi screens , 2006, Genome Biology.

[63]  M. Imai,et al.  Dual Wavelength Imaging Allows Analysis of Membrane Fusion of Influenza Virus inside Cells , 2006, Journal of Virology.

[64]  Gerhard Grüber,et al.  A WNK kinase binds and phosphorylates V‐ATPase subunit C , 2006, FEBS letters.

[65]  B. Moss.  Poxvirus entry and membrane fusion. , 2006, Virology.

[66]  B. Lina,et al.  Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. , 2005, Antiviral research.

[67]  Ron Shamir,et al.  EXPANDER – an integrative program suite for microarray data analysis , 2005, BMC Bioinformatics.

[68]  Jeffrey W. Clark,et al.  Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors , 2005, Clinical Cancer Research.

[69]  R. Eisenberg,et al.  Glycoprotein D Receptor-Dependent, Low-pH-Independent Endocytic Entry of Herpes Simplex Virus Type 1 , 2005, Journal of Virology.

[70]  Jens C. Streibig,et al.  Bioassay analysis using R , 2005 .

[71]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[72]  Thorsten Wolff,et al.  MEK inhibition impairs influenza B virus propagation without emergence of resistant variants , 2004, FEBS letters.

[73]  Ron Shamir,et al.  CLICK and EXPANDER: a system for clustering and visualizing gene expression data , 2003, Bioinform..

[74]  P. Palese,et al.  Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses. , 2003, Virus research.

[75]  Michael T. McManus,et al.  RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[76]  H. Hirte,et al.  BAY 43-9006: early clinical data in patients with advanced solid malignancies. , 2002, Current pharmaceutical design.

[77]  H. Narita,et al.  In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705 , 2002, Antimicrobial Agents and Chemotherapy.

[78]  R. Lamb,et al.  Influenza A Virus M2 Ion Channel Activity Is Essential for Efficient Replication in Tissue Culture , 2002, Journal of Virology.

[79]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[80]  R. Webster,et al.  A DNA transfection system for generation of influenza A virus from eight plasmids. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[81]  S. Capitani,et al.  PMA‐induced megakaryocytic differentiation of HEL cells is accompanied by striking modifications of protein kinase C catalytic activity and isoform composition at the nuclear level , 1996, British journal of haematology.

[82]  A. Helenius,et al.  Virus Entry into Animal Cells , 1989, Advances in Virus Research.

[83]  A Helenius,et al.  Infectious entry pathway of influenza virus in a canine kidney cell line , 1981, The Journal of cell biology.

[84]  R. Tripp,et al.  Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication. , 2015, Assay and drug development technologies.

[85]  F. Hayden,et al.  Emerging influenza antiviral resistance threats. , 2011, The Journal of infectious diseases.

[86]  L. Aschenbrenner,et al.  Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. , 2011, The Journal of antimicrobial chemotherapy.

[87]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..